Dual-targeted regimens for the frontline treatment of CLL
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):421-426. doi: 10.1182/hematology.2023000506.ABSTRACTThe treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20-directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors hav...
Source: Hematology ASH Education Program - December 9, 2023 Category: Hematology Authors: Chaitra Ujjani Source Type: research
Dual-targeted regimens for the frontline treatment of CLL
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):421-426. doi: 10.1182/hematology.2023000506.ABSTRACTThe treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20-directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors hav...
Source: Hematology ASH Education Program - December 9, 2023 Category: Hematology Authors: Chaitra Ujjani Source Type: research
